Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer enters deal for targeted cancer drugs

This article was originally published in Scrip

Executive Summary

Pfizer signed a deal with a biotech startup to develop a new generation of targeted antibody drugs for cancer.

You may also be interested in...



AbbVie Partnership On CD71 Gives CytomX Big Upfront, Co-Promotion Potential

Antibody-drug conjugates have taken a back seat to cancer immunotherapy as the hot modality in oncology of late, but AbbVie Inc. and CytomX Therapeutics Inc. unveiled a partnership on April 20 to develop an ADC in a deal that CytomX cites as further validation of its Probody technology platform.

Baxter's Advate helps prevent bleeding in one-year study of hemophiliacs

Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.

Mylan CEO Bresch is looking to do a sizable deal

Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.

Topics

Related Companies

UsernamePublicRestriction

Register

SC021648

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel